Triple oral beta-lactam containing therapy for Buruli ulcer treatment shortening.
PLoS Negl Trop Dis
; 13(1): e0007126, 2019 01.
Article
em En
| MEDLINE
| ID: mdl-30689630
ABSTRACT
The potential use of clinically approved beta-lactams for Buruli ulcer (BU) treatment was investigated with representative classes analyzed in vitro for activity against Mycobacterium ulcerans. Beta-lactams tested were effective alone and displayed a strong synergistic profile in combination with antibiotics currently used to treat BU, i.e. rifampicin and clarithromycin; this activity was further potentiated in the presence of the beta-lactamase inhibitor clavulanate. In addition, quadruple combinations of rifampicin, clarithromycin, clavulanate and beta-lactams resulted in multiplicative reductions in their minimal inhibitory concentration (MIC) values. The MIC of amoxicillin against a panel of clinical isolates decreased more than 200-fold within this quadruple combination. Amoxicillin/clavulanate formulations are readily available with clinical pedigree, low toxicity, and orally and pediatric available; thus, supporting its potential inclusion as a new anti-BU drug in current combination therapies.
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Beta-Lactamases
/
Mycobacterium ulcerans
/
Úlcera de Buruli
/
Inibidores de beta-Lactamases
Limite:
Humans
Idioma:
En
Ano de publicação:
2019
Tipo de documento:
Article